16 citations
,
May 2020 in “Journal of The European Academy of Dermatology and Venereology” This publication involves a case-series report on the treatment of male and female pattern hair loss using sublingual minoxidil in 64 patients, but it does not include an abstract or results.
5 citations
,
August 2021 in “Journal of The European Academy of Dermatology and Venereology” In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.
May 2026 in “Journal of the American Academy of Dermatology” In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.
May 2026 in “Clinical and Experimental Dermatology” This study reports a 10-year-old boy with ectodermal dysplasia and progressive balding experienced reduced hair shedding and increased hair density after four months of sublingual minoxidil treatment, without side-effects.
January 2026 in “Frontiers in Pharmacology” This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.